Robert J. Polzer serves as the Executive Vice President and President of Research and Development at Zoetis Inc Class A, a leading animal health company. With a robust background in pharmaceuticals and life sciences, Polzer has been instrumental in driving innovation and growth within the organization. He joined Zoetis in 2012, prior to its spin-off from Pfizer, and has since played a pivotal role in shaping the company's R&D strategy. His leadership has been crucial in advancing Zoetis' portfolio of products and services, which cater to the health and well-being of animals across various species. Before joining Zoetis, Polzer held several key positions at Pfizer, where he spent over two decades. His tenure at Pfizer included roles in both human and animal health divisions, giving him a comprehensive understanding of the pharmaceutical industry. At Pfizer, he was involved in numerous drug development projects and was recognized for his strategic vision and ability to lead cross-functional teams. Polzer's expertise in R&D has been a significant asset to Zoetis, where he oversees a global team of scientists and researchers dedicated to discovering and developing new therapies and vaccines. Under Polzer's leadership, Zoetis has achieved several milestones, including the launch of groundbreaking products that have improved animal health outcomes worldwide. His commitment to innovation is evident in the company's investment in cutting-edge technologies and research initiatives. Polzer's strategic direction has not only enhanced Zoetis' competitive edge but also solidified its reputation as a leader in the animal health industry. His vision for the future of veterinary medicine continues to drive the company's mission to nurture and protect the health of animals and the people who care for them.